{
    "2018-03-26": [
        [
            {
                "time": "2018-03-26",
                "original_text": "Fair, equitable trade' is in everyone's best interests: ...",
                "features": {
                    "keywords": [
                        "equitable",
                        "trade",
                        "interests"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Open trade is ultimately in 'everyone's best interest,' Johnson & Johnson CEO says",
                "features": {
                    "keywords": [
                        "open trade",
                        "Johnson & Johnson",
                        "CEO"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "CNBC Transcript: Alex Gorsky, Chairman & CEO, Johnson & Johnson",
                "features": {
                    "keywords": [
                        "CNBC",
                        "transcript",
                        "Alex Gorsky",
                        "Chairman",
                        "CEO",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Johnson & Johnson Investors",
                "features": {
                    "keywords": [
                        "JNJ",
                        "investor alert",
                        "securities class action",
                        "Johnson & Johnson investors"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Don't Worry, Pfizer Isn't Out of Options for Its Consumer Health Division Just Yet",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "consumer health division",
                        "options"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "A Biotech Collapses: Is Buying Now 'Futile'?",
                "features": {
                    "keywords": [
                        "biotech",
                        "collapses",
                        "buying",
                        "futile"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Why Protagonist Therapeutics, Inc. Is Imploding Today",
                "features": {
                    "keywords": [
                        "Protagonist Therapeutics",
                        "imploding"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "drops bid",
                        "Pfizer",
                        "Shingrix",
                        "EU/Japan nod"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Novartis Gets Positive CHMP Opinion on Biosimilar Remicade",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CHMP opinion",
                        "biosimilar",
                        "Remicade"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Is Pfizer's Best Option Now a Consumer Healthcare Spinoff?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "consumer healthcare",
                        "spinoff"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer",
                "features": {
                    "keywords": [
                        "Zacks",
                        "analyst blog",
                        "AbbVie",
                        "J&J",
                        "Heron Therapeutics",
                        "Roche",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Better Stock: Verizon Communications Inc. (VZ) vs. Johnson & Johnson (JNJ)",
                "features": {
                    "keywords": [
                        "better stock",
                        "Verizon",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "telecommunications",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "See what the IHS Markit Score report has to say about Johnson & Johnson.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "report",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-26",
                "original_text": "Yahoo Finance Live: Market Movers - Mar 26, 2018",
                "features": {
                    "keywords": [
                        "Yahoo Finance Live",
                        "market movers"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}